{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:10:36Z","timestamp":1794967836125,"version":"4.9.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007582","name":"Alberta Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014735","name":"Royal College of Physicians and Surgeons of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018825","name":"Minist\u00e8re de la D\u00e9fense Nationale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202110MFE-472921-HTB-272687"],"award-info":[{"award-number":["202110MFE-472921-HTB-272687"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.neubiorev.2025.106163","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:58:05Z","timestamp":1744725485000},"page":"106163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review"],"prefix":"10.1016","volume":"173","author":[{"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Zeifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Swainson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Balachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Reichelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Burback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Greenshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vermetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jetly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-1173","authenticated-orcid":false,"given":"Venkat","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2025.106163_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/adb0000935","article-title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis","volume":"38","author":"Agin-Liebes","year":"2024","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.neubiorev.2025.106163_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neubiorev.2025.106163_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2016.02.008","article-title":"The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases","volume":"64","author":"Aznar","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neubiorev.2025.106163_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib7","first-page":"129","article-title":"An Evaluation of Cognitive Behavioral Therapy for Substance Use Disorder: A Systematic Review and Application of the Society of Clinical Psychology Criteria for Empirically Supported Treatments","volume":"30","author":"Boness","year":"2023","journal-title":"Clin. Psychol. Publ. Div. Clin. Psychol. Am. Psychol. Assoc."},{"key":"10.1016\/j.neubiorev.2025.106163_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106163_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106163_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106163_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000128","article-title":"What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review","volume":"6","author":"Castro Santos","year":"2021","journal-title":"Porto Biomed. J."},{"key":"10.1016\/j.neubiorev.2025.106163_bib12","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.neubiorev.2025.106163_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: A systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neubiorev.2025.106163_bib15","unstructured":"Drugs [WWW Document], n.d. URL \u3008https:\/\/www.who.int\/health-topics\/drugs-psychoactive\u3009 (accessed 11.30.24)."},{"key":"10.1016\/j.neubiorev.2025.106163_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11920-019-1086-0","article-title":"Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies","volume":"21","author":"Fadus","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction","volume":"7","author":"Garcia-Romeu","year":"2015","journal-title":"Curr. Drug Abus. Rev."},{"key":"10.1016\/j.neubiorev.2025.106163_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default Mode Network Modulation by Psychedelics: A Systematic Review","volume":"26","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106163_bib20","first-page":"4","article-title":"Addiction and Cognition","volume":"5","author":"Gould","year":"2010","journal-title":"Addict. Sci. Clin. Pr."},{"key":"10.1016\/j.neubiorev.2025.106163_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib22","series-title":"Supplementary Guidance for Inclusion of Qualitative Research in Cochrane Systematic Reviews of Interventions. Version 1 (updated August 2011)","article-title":"Chapter 4: Critical appraisal of qualitative research","author":"Hannes","year":"2011"},{"key":"10.1016\/j.neubiorev.2025.106163_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1215972","article-title":"Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder","volume":"14","author":"Heinzerling","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib24","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ Online"},{"key":"10.1016\/j.neubiorev.2025.106163_bib25","first-page":"14","article-title":"Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis","author":"Irizarry","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.neubiorev.2025.106163_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neubiorev.2025.106163_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neubiorev.2025.106163_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.neubiorev.2025.106163_bib30","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib32","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1176\/appi.ajp.2020.20091382","article-title":"Substance Use Disorders and Addiction: Mechanisms, Trends, and Treatment Implications","volume":"177","author":"Kalin","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.neubiorev.2025.106163_bib35","doi-asserted-by":"crossref","DOI":"10.47626\/2237-6089-2022-0597","article-title":"Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence","author":"Koning","year":"2024","journal-title":"Trends Psychiatry Psychother. 46, e20220597"},{"key":"10.1016\/j.neubiorev.2025.106163_bib36","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: More questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106163_bib38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib39","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1037\/ccp0000447","article-title":"A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition","volume":"87","author":"Magill","year":"2019","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106163_bib40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/10826084.2021.1899220","article-title":"Examining the Role of Craving, Mindfulness, and Psychological Flexibility in a Sample of Individuals with Substance Use Disorder","volume":"56","author":"Mallik","year":"2021","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.neubiorev.2025.106163_bib41","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41591-021-01530-3","article-title":"Psychedelic therapy: a roadmap for wider acceptance and utilization","volume":"27","author":"Marks","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.neubiorev.2025.106163_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0306-4603(02)00294-0","article-title":"Harm reduction approaches to alcohol use: health promotion, prevention, and treatment","volume":"27","author":"Marlatt","year":"2002","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neubiorev.2025.106163_bib43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.neubiorev.2025.106163_bib44","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neubiorev.2025.106163_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.neubiorev.2025.106163_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s44220-024-00302-5","article-title":"Social identity processes as a vehicle for therapeutic success in psychedelic treatment","volume":"2","author":"Newson","year":"2024","journal-title":"Nat. Ment. Health"},{"key":"10.1016\/j.neubiorev.2025.106163_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","article-title":"Psilocybin: from ancient magic to modern medicine","volume":"73","author":"Nichols","year":"2020","journal-title":"J. Antibiot."},{"key":"10.1016\/j.neubiorev.2025.106163_bib48","first-page":"151","article-title":"The History of Psychedelics in Psychiatry","volume":"54","author":"Nichols","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neubiorev.2025.106163_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs\u2014a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106163_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pbb.2016.06.005","article-title":"Etiological theories of addiction: A comprehensive update on neurobiological, genetic and behavioural vulnerability","volume":"148","author":"Ouzir","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106163_bib52","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1038\/s41598-024-52967-8","article-title":"Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study","volume":"14","author":"Pagni","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2025.106163_bib54","article-title":"Cognitive inflexibility moderates the relationship between relief-driven drinking motives and alcohol use","volume":"20","author":"Piccoli","year":"2024","journal-title":"Addict. Behav. Rep."},{"key":"10.1016\/j.neubiorev.2025.106163_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.neubiorev.2025.106163_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","article-title":"Treatment Access Barriers and Disparities Among Individuals with Co-Occurring Mental Health and Substance Use Disorders: An Integrative Literature Review","volume":"61","author":"Priester","year":"2016","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.neubiorev.2025.106163_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neubiorev.2025.106163_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-010-2121-3","article-title":"Chronic ketamine use increases serum levels of brain-derived neurotrophic factor","volume":"215","author":"Ricci","year":"2011","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2025.106163_bib59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neubiorev.2025.106163_bib60","first-page":"81","article-title":"Treatment of alcoholism with psychotomimetic drugs. A follow-up study","volume":"20","author":"Rydzy\u0144ski","year":"1978","journal-title":"Act. Nerv. Super. (Praha)"},{"key":"10.1016\/j.neubiorev.2025.106163_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.3630","article-title":"Psychedelic and MDMA-Related Adverse Effects-A Call for Action","volume":"5","author":"Simonsson","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.neubiorev.2025.106163_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173603","article-title":"Role of social context in addiction etiology and recovery","volume":"229","author":"Strickland","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106163_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1406888","article-title":"Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder","volume":"15","author":"Szafoni","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106163_bib64","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.neubiorev.2025.106163_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14737175.2016.1220834","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"de Veen","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neubiorev.2025.106163_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic Advances from the Brain Disease Model of Addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2025.106163_bib67","unstructured":"Wells, G., Shea, B., O\u2019Connell, J., 2014. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses."},{"key":"10.1016\/j.neubiorev.2025.106163_bib68","unstructured":"World Health Organization, \u200e2024\u200e. Global status report on alcohol and health and treatment of substance use disorders. World Health Organization. \u3008https:\/\/iris.who.int\/handle\/10665\/377960\u3009."},{"key":"10.1016\/j.neubiorev.2025.106163_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neubiorev.2025.106163_bib70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.neuroimage.2019.06.036","article-title":"Brain default-mode network dysfunction in addiction","volume":"200","author":"Zhang","year":"2019","journal-title":"NeuroImage"}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:19:58Z","timestamp":1774516798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763425001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"alternative-id":["S0149763425001630"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106163","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106163"}}